Teva Pharmaceutical Industries believes the restructuring and portfolio optimization it has conducted in its North American Generics operation, coupled with a healthy roster of upcoming launches, should sustain the business’ annual sales at around $4bn per year.
In the second quarter of this year, Teva’s North American Generics turnover dipped by just $1m to $946m, with recent...




